BOLT | tickerfilter.com

Fundamental analysis

27%

Profitability 0%

Dept financing 21%

Liquidity 50%

Performance 50%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-3.50%

1 Month

-17.72%

3 Months

-26.30%

6 Months

-26.30%

1 Year

-26.30%

2 Year

-26.30%

Key data

Stock price

$0.34

P/E Ratio

0.00

DAY RANGE

$0.31 - $0.35

EPS

-$0.41

52 WEEK RANGE

$0.31 - $0.48

52 WEEK CHANGE

-$26.30

MARKET CAP

20.480 M

YIELD

N/A

SHARES OUTSTANDING

0.000

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-13-2025

BETA

0.00

PUBLIC FLOAT

N/A

AVERAGE 10 VOLUME

$156,896

AVERAGE 30 VOLUME

$150,838

Company detail

CEO: Randall C. Schatzman
Region: US
Website: boltbio.com
Employees: 90
IPO year: 2021

Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Bolt Biotherapeutics, Inc. engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors.

BOLT - Bolt Biotherapeutics, Inc.